Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364882 · ClinicalTrials.gov registry record · Phase 1
A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women
A Phase 1 study, sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02364882 is a Phase 1 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 21 participants.
The verdict
NCT02364882, a Phase 1 study, has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a Phase 1, single center, open-label, within-subject dose-escalation study evaluating the safety and pharmacokinetics of SST-6006 in healthy postmenopausal women. Three dose levels of SST-6006 and a placebo regimen will be evaluated: 1 g (0 mg of sildenafil), 1 g (50 mg of sildenafil), 2 g (100 mg of sildenafil), and 4 g (200 mg of sildenafil). Doses will be administered sequentially and will be separated by a 14-16 day washout period. All 3 dose levels and the placebo will be applied both externally and internally.
Interventions
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02364882
The ClinicalTrials.gov registry entry for NCT02364882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sildenafil is the first listed.
NCT02364882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02364882 about?
NCT02364882 is a clinical study titled "A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women". This is a Phase 1, single center, open-label, within-subject dose-escalation study evaluating the safety and pharmacokinetics of SST-6006 in healthy postmenopausal women. Three dose levels of SST-6006 and a placebo regimen will be evaluated: 1 g (0 mg of sildenafil), 1 g (50 mg of sildenafil), 2 g (...
What is the current status of trial NCT02364882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-01. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02364882?
The interventions under investigation include: Sildenafil (DRUG).
Who is sponsoring clinical trial NCT02364882?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.